An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making ...

More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi (formerly STS101) has ...

A budget proposal from President Donald Trump’s administration would cut a federal grant that provides $56 million annually ...

The Trump administration has proposed terminating a $56 million annual grant program that distributes naloxone, also known by ...

The US Food and Drug Administration (FDA) has approved Atzumi, a 5.2 mg dihydroergotamine (DHE) nasal powder, for the acute ...

A drug derived from ketamine will be added to the PBS, helping tens of thousands of Australians struggling with depression to ...

The studies showed that the nasal powder had rapid absorption, rapid achievement of high DHE plasma concentrations, and sustained DHE plasma levels. The drug was well tolerated when used long-term ...

Naloxone, which can reverse overdoses of opioids, has been available in the U.S. without a prescription since March of 2023, ...

Montgomery County is attributing a dramatic decline in drug deaths to efforts to prevent them, including availability of a ...

Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who ...

The FDA has approved Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

The recommended dose of Atzumi is 5.2mg, the contents of 1 nasal device, administered into 1 nostril. The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal ...